Hairy Cell Leukemia Variant
Associated Genetic Biomarkers
NCI Definition: An indolent chronic B-cell leukemia resembling classic hairy cell leukemia but shows variant cytologic, hematologic, and immunophenotypic features and is resistant to the conventional therapy applied to hairy cell leukemia. Biologically, it is not related to hairy cell leukemia. 
Hairy cell leukemia variants most frequently harbor alterations in TP53, NOTCH2, KDM6A, and BTK .
TP53 c.217-c.1178 Missense, TP53 V173M, TP53 Mutation, TP53 Missense, and TP53 Exon 5 Mutation are the most common alterations in hairy cell leukemia variant .
There are 6 clinical trials for hairy cell leukemia variant, of which 6 are open and 0 are completed or closed. Of the trials that contain hairy cell leukemia variant as an inclusion criterion, 2 are phase 1 (2 open) and 4 are phase 2 (4 open).
CD22, CD19, and ITGAX are the most frequent gene inclusion criteria for hairy cell leukemia variant clinical trials .
Rituximab, cd22 car t-cell immunotherapy, and bendamustine are the most common interventions in hairy cell leukemia variant clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.